Vanda Pharmaceuticals (VNDA) Tops Q2 EPS by 31c
Tweet
Share
E-mail
Get Alerts VNDA Hot Sheet
Price: $5.04 -4%
Revenue Growth %: +24.1%
Financial Fact:
Income (loss) from operations: -653K
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +24.1%
Financial Fact:
Income (loss) from operations: -653K
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q2 EPS of $0.03, $0.31 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $42.06 million versus the consensus estimate of $40.31 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
- Macy's (M) Tops Q2 EPS by 28c, Beats on Revenue; Offers FY Guidance
- Champions Oncology (CSBR) Tops Q1 EPS by 6c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
